1Lenzen R, Borchard F, Lubke H, et al. Colitis ulcerosa complicated by malignant lymphoma: case report and analysis of published works. Gut, 1995,36:306-310. 被引量：1
2Kopdcova M, Rejchrt S. Tycova V, et al. Tumorous neo- vaseularization: a newly recognized endoscopic feature of intestinal non- Hodgkin lymphoma. Endoscopy. 2007.39 Suppl 1: E95. 被引量：1
3Garcia-Sanchez MV, Poyato-Gonzalez A, Giraldez-Jimenez MD, et al. MALT lymphoma in a patient with Crohn's disease. A causal or incidental association? Gastroenterol Hepatol, 2006,29 : 74-76. 被引量：1
4Bernstein CN, Blanchard JF, Kliewer E, et al. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer, 2001,91 : 854-862. 被引量：1
5Van Domselaar M, Lopez San Roman A. Bastos Oreiro M,et al. Lymphoproliferative disorders in an inflammatory bowel disease unit. Gastroenterol Hepatol, 2010,33 : 12-16. 被引量：1
6Kandiel A, Fraser AG, Knrelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6 mereaptopurine. Gut, 2005, 54: 1121-1125. 被引量：1
7Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009.374: 1617-1625. 被引量：1
8Lopez San Romcin A. Van Domselaar M, Rivero M, et al. Complete remission of a primary rectal lymphoma on ulcerative colitis, after withdrawal of azathioprine and inlliximab. J Crohns Colitis, 2008,2..93-96. 被引量：1
9Askling J, Brandt L, Lapidus A,et al. Risk of haematopoietie cancer in patients with inflammatory bowel disease. Gut. 2005,54:617-622. 被引量：1
10Fraser AG, Orchard TR, Robinson EM, et al. Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Aliment Pharmacol Ther, 2002, 16: 1225-1232. 被引量：1
